Immunotherapy with dog and cat extracts in children

Area of Science:

• Pediatric Allergy and Immunology
• Respiratory Medicine
• Clinical Therapeutics

Background:

• Pet allergies, specifically to dogs and cats, are a common trigger for childhood asthma.
• Conventional medical therapies offer symptomatic relief but do not address the underlying allergic sensitization.

Purpose of the Study:

• To evaluate the efficacy of immunotherapy as an add-on treatment for children with asthma induced by dog or cat allergies.
• To determine if immunotherapy can improve clinical outcomes beyond standard medical care.

Main Methods:

• An open, controlled clinical study involving 27 children (mean age 10.75 years) with confirmed dog/cat allergies.
• Patients were randomized to receive either subcutaneous immunotherapy with alum-adsorbed depot extract or conventional therapy.
• Evaluations included bronchial provocation tests (BPT), skin prick tests (SPT), specific IgE (RAST), and IgG4 levels before and after 9 months of treatment.

Main Results:

• The immunotherapy group demonstrated a statistically significant improvement in bronchial tolerance (P < 0.02) compared to the control group (P > 0.05).
• A significantly greater reduction in skin sensitivity was observed in the active treatment group (P < 0.05).
• While RAST and IgG4 levels showed no significant differences overall, a notable increase in IgG4 was observed in the immunotherapy group (P = 0.05).

Conclusions:

• Immunotherapy is a recommended supplementary treatment for children suffering from dog- and cat-induced asthma.
• The study supports immunotherapy's role in enhancing bronchial tolerance and reducing allergic skin responses in pediatric patients.
• The observed side effects were acceptable, suggesting a favorable safety profile for this therapeutic approach.